Background:
- Pazopanib is an anticancer drug that blocks the growth of new blood vessels in tumors. It
has been approved to treat renal cell cancer. ARQ 197 is an experimental drug that blocks a
protein called c-MET, which cancer cells need to grow. Studies suggest that some drugs that
block blood vessel growth can increase the production of c-MET in tumors, which helps cancer
cells keep growing. Blocking both blood vessel growth and c-MET with pazopanib and ARQ 197
may help kill cancer cells faster. This study will use these drugs to treat solid tumors that
have not responded to earlier treatments.
Objectives:
- To test the safety and effectiveness of pazopanib and ARQ 197 for advanced solid tumors.
Eligibility:
- Individuals at least 18 years of age who have advanced solid tumors that have not responded
to earlier treatments.
Design:
- Participants will be screened with a physical exam and medical history. They will also
have blood and urine tests, and imaging studies.
- The study drugs will be given in 4-week cycles of treatment. Participants will take
pazopanib once a day and ARQ 197 twice a day by mouth. Some participants will start with
pazopanib or ARQ 197 alone for the first week. Then they will take both drugs together
for the rest of the study.
- Participants will be monitored with frequent blood tests and imaging studies. Optional
tumor samples may be collected during different treatment cycles.